养心汤含药血清对H_2O_2诱导内皮损伤模型差异基因及ST3GAL2mRNA表达的影响
|
摘要
目的:通过观察养心汤含药血清对过氧化氢诱导人脐静脉内皮细胞氧化损伤模型差异基因及ST3GAL2mRNA表达的影响,探讨其内皮保护机制,为早期防治冠心病不稳定型心绞痛提供客观依据。
方法:采用过氧化氢体外诱导人脐静脉内皮细胞氧化损伤的方法,建立人脐静脉内皮细胞氧化损伤模型。实验一分为①空白血清组;②模型组;③养心汤含药血清2%组;④养心汤含药血清4%组;⑤养心汤含药血清6%组;⑥养心汤含药血清8%组。倒置显微镜下观察细胞形态、密度,MTT法测定各组细胞增殖活性。实验二分为①空白组;②模型组;③养心汤含药血清组,应用Affymetrix人基因组U133+2.0芯片观察养心汤含药血清对过氧化氢诱导的人脐静脉内皮细胞氧化损伤模型的差异基因表达的影响,并采用实时定量PCR方法对人脐静脉内皮细胞氧化损伤模型ST3GAL2mRNA的表达进行验证。
结果:1.各组人脐静脉内皮细胞形态学改变:在倒置显微镜下可观察到,正常内皮细胞排列紧密,呈铺路石状。过氧化氢作用2h后,细胞变圆,开始脱落,细胞间隙增宽,密度明显降低,细胞呈梭形,细胞核折光性增强。养心汤含药血清2%、4%、6%、8%组细胞形态有所改善,轮廓相对融合。其中养心汤含药血清6%、8%组细胞变形、皱缩的程度减轻最为明显;2.与空白血清组比较,模型组细胞光密度值、增殖率均降低,其差异显著,具有统计学意义(P均<0.01)。与模型组比较,养心汤含药血清2%组细胞光密度值、增殖率均升高,差异无统计学意义(P均>0.05),养心汤含药血清4%、6%、8%组细胞光密度值、增殖率均升高,差异显著,具有统计学意义(P均<0.01)。与养心汤含药血清6%组比较,养心汤含药血清2%、4%组的细胞光密度值、增殖率均降低,差异显著,具有统计学意义(P均<0.01);养心汤含药血清8%组的细胞光密度值、增殖率均降低,差异无统计学意义(P均>0.05);3.模型组与空白组比较表达上调,养心汤含药血清组与模型组比较表达下调的基因有23个,模型组与空白组比较表达下调,养心汤含药血清组与模型组比较表达上调的基因有12个,经MAS分析后,养心汤含药血清干预人脐静脉内皮细胞氧化损伤模型差异基因的功能主要集中在与核酸结合、与蛋白激酶结合、蛋白质合成和转运、血小板活化、细胞黏附等方面;4.养心汤含药血清组ST3GAL2mRNA表达量为模型组的0.375倍,与基因芯片检测结果基本一致。
结论:1.养心汤含药血清可以减轻过氧化氢对人脐静脉内皮细胞增殖的抑制作用;2.养心汤含药血清干预人脐静脉内皮细胞氧化损伤模型差异基因的功能主要集中在与核酸结合、与蛋白激酶结合、蛋白质合成和转运、血小板活化、细胞黏附等方面;3.养心汤含药血清可明显下调人脐静脉内皮细胞氧化损伤模型ST3GAL2mRNA表达水平,这可能是其保护内皮细胞损伤,防治冠心病不稳定型心绞痛的机制之一。
Objective:To observe the effects the formula of the serum with Yangxin Decoction on the oxidative damage of human umbilical vein endothelial cell’different genes expressions.To investigate its mechanics, then to provide academic warranties for preventing and curing the atherosc- lerosis early.
Methods:Establishing the Cell models of the oxidative damage of human umbilical vein endothelial cell with the method of interferencing Hydrogen peroxide to human umbilical vein endothelial cell. Deviding the human umbilical vein endothelial cell into six groups random.①The blank control group ;②The model group;③the serum with Yangxin Decoction 2% group;④the serum with Yangxin Decoction 4% group;⑤the serum with Yangxin Decoction 6% group;⑥the serum with Yangxin Decoction 8% group.Observe cellular form, density Under inverted microscope. examine cellular viability with MTT.To observe the effects the formula of the serum with Yangxin Decoction on the oxidative damage of human umbilical vein endothelial cell’different genes expressions. To examine the expression of ST3GAL2mRNA with RT-PCR method.
Result:1.The morphologic change of human umbilical vein endothel- ial cell: Normal umbilical vein endothelial cell’s closely arranged, cobble- stone-like under the inverted microscope. The cell tunes to be round, falls off and the intercellular space broadens, the density reduces obviously, the cell looks like spindle-shaped, nucleus diffraction enhances after 100μmol L-1 hydrogen peroxide affects 2h;2.Model group was significantly lower than the blank control group in OD, statistically significant difference (P<0.01).Compared with model group, the serum with Yangxin Decoction 2% group has no significant difference(P>0.05) , the serum with Yangxin Decoction 4%、6%、8% group have significant differences(P<0.01). Compared with the serum with Yangxin Decoction 6%, the serum with Yangxin Decoction 2%、4%group have significant differences(P<0.01),the serum with Yangxin Decoction 8% group has no significant difference(P> 0.05);3.Model group compared with the blank control group upregulation, the serum with Yangxin Decoction compared with the model group downreg- ulation12 genes,Model group compared with the blank control group down- regulation, the serum with Yangxin Decoction compared with the model gro- up upregulation23 genes;4. The serum with Yangxin Decoction’expression of ST3GAL2mRNA 0.375 times for the model group,this is consistent with microarray results.
Conclusions:1.The serum with Yang xin Decoction can reduce the inhibiti- on in which hydrogen peroxide effect human umbilical vein endothelial cell proliferation;2.The serum with Yangxin Decoction’different gene functions mainly in DNA binding,protein synthesis and transport,kinase,Platelet acti- vation,cell adhesion,etc;3.The serum with Yangxin Decoction can significa- ntly lower the oxidative injury model’ST3GAL2mRNA expression,which may be its function mechanism of its preventing and curing atherosclerosis.
方法:采用过氧化氢体外诱导人脐静脉内皮细胞氧化损伤的方法,建立人脐静脉内皮细胞氧化损伤模型。实验一分为①空白血清组;②模型组;③养心汤含药血清2%组;④养心汤含药血清4%组;⑤养心汤含药血清6%组;⑥养心汤含药血清8%组。倒置显微镜下观察细胞形态、密度,MTT法测定各组细胞增殖活性。实验二分为①空白组;②模型组;③养心汤含药血清组,应用Affymetrix人基因组U133+2.0芯片观察养心汤含药血清对过氧化氢诱导的人脐静脉内皮细胞氧化损伤模型的差异基因表达的影响,并采用实时定量PCR方法对人脐静脉内皮细胞氧化损伤模型ST3GAL2mRNA的表达进行验证。
结果:1.各组人脐静脉内皮细胞形态学改变:在倒置显微镜下可观察到,正常内皮细胞排列紧密,呈铺路石状。过氧化氢作用2h后,细胞变圆,开始脱落,细胞间隙增宽,密度明显降低,细胞呈梭形,细胞核折光性增强。养心汤含药血清2%、4%、6%、8%组细胞形态有所改善,轮廓相对融合。其中养心汤含药血清6%、8%组细胞变形、皱缩的程度减轻最为明显;2.与空白血清组比较,模型组细胞光密度值、增殖率均降低,其差异显著,具有统计学意义(P均<0.01)。与模型组比较,养心汤含药血清2%组细胞光密度值、增殖率均升高,差异无统计学意义(P均>0.05),养心汤含药血清4%、6%、8%组细胞光密度值、增殖率均升高,差异显著,具有统计学意义(P均<0.01)。与养心汤含药血清6%组比较,养心汤含药血清2%、4%组的细胞光密度值、增殖率均降低,差异显著,具有统计学意义(P均<0.01);养心汤含药血清8%组的细胞光密度值、增殖率均降低,差异无统计学意义(P均>0.05);3.模型组与空白组比较表达上调,养心汤含药血清组与模型组比较表达下调的基因有23个,模型组与空白组比较表达下调,养心汤含药血清组与模型组比较表达上调的基因有12个,经MAS分析后,养心汤含药血清干预人脐静脉内皮细胞氧化损伤模型差异基因的功能主要集中在与核酸结合、与蛋白激酶结合、蛋白质合成和转运、血小板活化、细胞黏附等方面;4.养心汤含药血清组ST3GAL2mRNA表达量为模型组的0.375倍,与基因芯片检测结果基本一致。
结论:1.养心汤含药血清可以减轻过氧化氢对人脐静脉内皮细胞增殖的抑制作用;2.养心汤含药血清干预人脐静脉内皮细胞氧化损伤模型差异基因的功能主要集中在与核酸结合、与蛋白激酶结合、蛋白质合成和转运、血小板活化、细胞黏附等方面;3.养心汤含药血清可明显下调人脐静脉内皮细胞氧化损伤模型ST3GAL2mRNA表达水平,这可能是其保护内皮细胞损伤,防治冠心病不稳定型心绞痛的机制之一。
Objective:To observe the effects the formula of the serum with Yangxin Decoction on the oxidative damage of human umbilical vein endothelial cell’different genes expressions.To investigate its mechanics, then to provide academic warranties for preventing and curing the atherosc- lerosis early.
Methods:Establishing the Cell models of the oxidative damage of human umbilical vein endothelial cell with the method of interferencing Hydrogen peroxide to human umbilical vein endothelial cell. Deviding the human umbilical vein endothelial cell into six groups random.①The blank control group ;②The model group;③the serum with Yangxin Decoction 2% group;④the serum with Yangxin Decoction 4% group;⑤the serum with Yangxin Decoction 6% group;⑥the serum with Yangxin Decoction 8% group.Observe cellular form, density Under inverted microscope. examine cellular viability with MTT.To observe the effects the formula of the serum with Yangxin Decoction on the oxidative damage of human umbilical vein endothelial cell’different genes expressions. To examine the expression of ST3GAL2mRNA with RT-PCR method.
Result:1.The morphologic change of human umbilical vein endothel- ial cell: Normal umbilical vein endothelial cell’s closely arranged, cobble- stone-like under the inverted microscope. The cell tunes to be round, falls off and the intercellular space broadens, the density reduces obviously, the cell looks like spindle-shaped, nucleus diffraction enhances after 100μmol L-1 hydrogen peroxide affects 2h;2.Model group was significantly lower than the blank control group in OD, statistically significant difference (P<0.01).Compared with model group, the serum with Yangxin Decoction 2% group has no significant difference(P>0.05) , the serum with Yangxin Decoction 4%、6%、8% group have significant differences(P<0.01). Compared with the serum with Yangxin Decoction 6%, the serum with Yangxin Decoction 2%、4%group have significant differences(P<0.01),the serum with Yangxin Decoction 8% group has no significant difference(P> 0.05);3.Model group compared with the blank control group upregulation, the serum with Yangxin Decoction compared with the model group downreg- ulation12 genes,Model group compared with the blank control group down- regulation, the serum with Yangxin Decoction compared with the model gro- up upregulation23 genes;4. The serum with Yangxin Decoction’expression of ST3GAL2mRNA 0.375 times for the model group,this is consistent with microarray results.
Conclusions:1.The serum with Yang xin Decoction can reduce the inhibiti- on in which hydrogen peroxide effect human umbilical vein endothelial cell proliferation;2.The serum with Yangxin Decoction’different gene functions mainly in DNA binding,protein synthesis and transport,kinase,Platelet acti- vation,cell adhesion,etc;3.The serum with Yangxin Decoction can significa- ntly lower the oxidative injury model’ST3GAL2mRNA expression,which may be its function mechanism of its preventing and curing atherosclerosis.
引文
1.周效勤.冠心病的气虚血瘀病机之我见[J].天津中医,2000,17(2):39-41.
2.梁煜,林代华,王清.气虚血瘀是冠心病的病机关键释义[J].中医药学刊,2003,21(4):588-589.
3.解民.从肝论治冠心病心绞痛的临床观察[J].吉林中医药,2002,22(4):5.
4.黎运富,彭素娟.中西医结合治疗冠心病不稳定性心绞痛56例总结[J].中医药药导报,2007,13(1):27-28.
5.祖丽华,秦玖刚.宣肺解郁汤联合西药治疗冠心病心绞痛40例[J].湖南中医药导报,2001,7(12):589,594.
6.樊瑞红.马连珍温阳活血法治疗冠心病心绞痛经验[J]辽宁中医杂志,2002,29(2):72.
7.陈维琴.黄蔑合丹参注射液治疗冠心病心绞痛40例[J].四川中医,2001,19(3):37-38.
8.于涛,曹洪欣.胸痹(冠心病)病机演变探微[J].中医药信息,2004,21(2):1-3.
9.杨传彪,周民权.论补养心阴法是治疗冠心病的重要方法[J].中国中医基础医学杂志,1998,4(6):45-47.
10.韩若冰.阴虚心痹临床探理[J].辽宁中医杂志,1987,(3):10-12.
11.程小曲.痰浊型冠心病与血脂、脂蛋白、载脂蛋白的关系及痰浊形成机理的探讨[J].新中医.1994,26(3):7-9.
12.王东生,袁肇凯,余亚明.痰瘀与动脉粥样硬化相关性探讨[J].山东中医药大学学报,2003,27(3):162-164.
13.范现超,张国平,唐明,等.从毒论治动脉粥样硬化初探[J].山东中医杂志,2004,23(5):261-263.
14.陆新.益气化湿活血通脉法治疗不稳定型心绞痛的临床观察[J].四川中医,2007,25(6):49-51.
15.董扬洲,毛湘屛.益气活血复脉汤治疗稳定型冠心病心绞痛32例临床观察[J].中医药导报,2008,14(7):20-21.
16.孙国柱.益气活血法治疗气虚血瘀型不稳定性心绞痛临床研究[J].河南中医学院学报,2005,20(4):35-36.
17.曹洪欣,殷惠军,张腾.温心胶囊抗动脉粥样硬化的形态学研究[J].中国中医药科技,2001,8(1):39.
18.唐丹丽,曹洪欣,张华敏.温阳益心法对动脉粥样硬化大鼠血清C反应蛋白和白细胞介素-6水平的影响[J].中国中医药信息杂志,2007,14(7):29-30.
19.孟强.通补结合治疗冠心病心绞痛66例疗效观察[J].山西中医,2005,21(6):18.
20.李晓,丁书文,姜萍.心和颗粒剂保护冠心病患者血管内皮损伤的临床研究[J].中医杂志,2000,41(11):661-663.
21.韩学杰.痰瘀同治方治疗冠心病心绞痛的临床研究[J].中国中医急症,1999,8(5):212-215.
22.李东柏.联用血府逐瘀胶囊治疗冠心病稳定性心绞痛40例的临床观察[J].北京中医药,2008,27(10):810-811.
23.何红涛.汪慰寒治疗冠心病心绞痛经验[J].辽宁中医药杂志,2006,33(1):15.
24.王嵩,刘煜德,李荣,等.清热解毒法对50例动脉粥样硬化患者血脂、纤维蛋白原、D-二聚体的干预作用[J].山西中医,2009,24(6):46-48.
25.王振涛,韩丽华,朱明军,等.孙建芝教授辨治冠心病经验[J].第十次全国中医心病学术年会论文集,2008:285-288.
26.吴耀南,谢俊杰,许正锦.路志正调理脾胃治疗胸痹的学术思想浅析[J].北京中医.2006,25(2):88-89.
27.刘侠,高彩霞,周玉凤.调理脾胃法治疗胸痹心痛100例[J].新中医,2002,34(7):55-56.
28.牛永军,曹雪梅.从脾胃论治胸痹举隅[J].实用中医内科杂志,2007,21(1):43.
29.罗陆一.从肾论治冠心病机理例析[J].中医药学刊,2005,23(4):588-589.
30.王剑,黄水清,徐志伟.瓜蒌薤白半夏汤对兔动脉粥样硬化模型主动脉蛋白聚糖的作用[J].中国动脉硬化杂志,2008,16(4):290-292.
31.何银辉,蔡奕,罗仕德.加味瓜蒌薤白半夏汤治疗冠心病心绞痛58例临床观察[J].中医药导报,2006,12(2):21-23.
32.潘健.中药治疗不稳定型心绞痛100例分析[J].实用中医内科杂志,2005,9(3):264.
33.王凤儒,李凤霞,戚彬.血府逐瘀汤治疗不稳定型心绞痛心血瘀阻型30例临床观察[J],黑龙江医药,2008,21(6):85-86.
34.文志斌,李俊成,何晓凡,等.四物汤对实验性血栓形成的影响[J].中国危重急救医学,1997,9(3):139-141.
35.邓春雷,陈熙.四物汤对血管内皮细胞分泌组织因子及其抑制物的影响[J].南华大学学报,2001,29(2);126-129.
36.蔡冬梅,殷胜利.吴伟康等.探讨补阳还五汤治疗气虚血瘀型冠心病的临床疗效以及与一氧化氮(NO)的关系[J].现代医学杂志,2004,32(1):5.
37.尚改萍,文志斌,何晓凡,等.补阳还五汤抗家兔动脉粥样硬化形成及机制[J].中国动脉硬化杂志,2002,10(2):112-114.
38.刘发益,文志斌,尚改萍,等.补阳还五汤抗家兔动脉粥样硬化形成的实验研究[J].湖南医科大学学报,2000,25(l):33-35.
39.徐丽萍.四逆汤的药理研究进展[J].中国药事,2002,6(l6):373.
40.高岚.四逆汤对左心室舒张功能的影响[J].现代中西医结合杂志,2000,9(2):112
41.孙慧兰,吴伟康.四逆汤有效成分不同组合抗心肌缺血再灌注损伤的作用研究[J].中草药,2002,33(4):333.
42.马文英,杨家声,弓翠春.复方丹参滴丸对血脂和血流动力学的影响[J].解放军药学学报,2001,17(1):47-81.
43.王有万,复方丹参滴丸对冠心病冠状动脉侧支循环和血运重建的临床观察[J].陕西中医学院学报,2008,31(1):25-26.
44.李耀民,刘向群,陈焕芹,等.复方丹参滴丸对大鼠动脉粥样硬化及TAFI水平的影响[J].中国老年学杂志,2009,29:280-281.
45.李艳平,席云霞.复方丹参滴丸治疗稳定型心绞痛疗效观察[J].临床军医杂志,2006,34(6):673-674.
46.黄元伟,王洪巨.通心络对不稳定型心绞痛患者血管内皮功能影响的临床研究[J].中国医学论坛报,2004,20.
47.李晋芳,胡长林,谢运兰,等.通心络对颈动脉粥样硬化炎性机制作用的临床研究[J].重庆医学,2006,35(8):712-713.
48.李越凡.心可舒治疗不稳定心绞痛疗效观察[J].中国社区医师,2006,8(15):64.
49.姜开余,顾振纶,阮长耿,等.丹参素对CDllb、P-selectin、ICAM-l、VCAM-l、E-selectin表达的影响.中国药理学通报,2001,16(6):682-5.
50.ChenYH,LinSJ,KuHH.Salvianolic acid B attenuates VCAM-1 and ICAM1expression in TNF-alpha-treated human aortic endothelial cell s [ J ] .J Cell Biochem,2001,82(3):512-21.
51.徐东波,张军平,张文志,等.丹参注射液对血管内皮细胞氧化损伤保护作用的实验研究[J].天津医科大学学报,2001,7(1):21-24.
52.侯团章.中草药提取物[M].中国医药科技出版社,2004,128-136.
53.吴勇,欧阳静萍,涂淑珍,等.黄芪多糖对动脉粥样硬化内皮细胞损伤的影响[J].湖北中医学院学报,2002,4(1):21-22.
54.杨五彪,陈群力,马灵筠,等.黄芪多糖对兔动脉粥样硬化血管内皮细胞功能的影响[J].陕西医学杂志,2005,8(34):914-918.
55.黄进宇,单江,徐耕,等.黄芪抑制血管平滑肌细胞增殖及其作用机制[J].中国现代应用药学杂志,2003,20:277-278.
56.WangM,Yang K E,Zhao D,et al.Effect of Panaxadiol Saponins on LPO, SODin Swimming Training Rats[J].Med Sci,2001,27(4):358-360.
57.李凤娥,孔繁利,李威.人参二醇组皂苷抗动脉粥样硬化作用实验研究[J].北华大学学报(自然科学版),2009,10(6):498-500.
58.戴汉云,等.绞股蓝皂贰对各种脂蛋白的影响[J].中草药,1989,20(4):172.
59.耿文奎,等.绞股蓝提取液对大鼠T淋巴细胞及脂类代谢的影响[J].广西医学,1988,10(l ) : 8 .
60.陈献明,等.绞股蓝总皂贰对鹤鹑实验性动脉粥样硬化预防作用的研究[J].山东医药工业,1992,11(l):22.
61.黄红林,尹卫东,廖端芳,等.绞股蓝总皂普对兔实验性动脉粥样硬化斑块形成的影响[J].中国动脉硬化杂志,1998,6(4):287.
62.Rhule A,N avarro S,Smith J R,et al.Panax notoginseng a t tenuates LPS-inducedproinflammatory mediators in RAW 264.7 cells [J].J E thnopharmacol, 2006,106(1):121-128.
63.闫彦芳,张壮,孙塑伦,等.三七总皂苷及其主要成分对血管内皮细胞缺氧损伤的保护作用[J].中国实验方剂学杂志,2002,8(1):34-37.
64.曾桂凤,刘建勋,李澎,等.丹参三七不同配比对缺氧复氧损伤人脐静脉内皮细胞的保护作用[J].精细化工,2006,23(2):126-129.
65.张希成,李刚.水蛭的药理与临床应用[J].医药产业资讯,2006,3(17):123.
66.刘晓颖,李凤文,张立石.水蛭对实验性动脉粥样硬化家兔血管内皮功能障碍的影响[J].中国中医基础医学杂志,1998,4(3):15-17.
67.才晓君,毕秀萍,王磊.生脉注射液对老年不稳定性心绞痛患者血浆炎性因子的影响[J].中国老年学杂志,2007,27:2228-2229.
68.汪根水.瓜蒌葛参汤联合生脉注射液治疗冠心病58例临床观察[J].中国中医药科技,2006,13(2):102.
69.贺厚毅,陈卫强.黄芪注射液治疗不稳定型心绞痛疗效观察[ J ] .中国自然医学杂志,2003,5(2):90-91.
70.郭跃来,于耀杰.黄芪注射液治疗老年不稳定型心绞痛30例[J].陕西中医,2006,27(7):846-847.
71.陈波,闫智杰,辛乐加.丹红注射液治疗不稳定型心绞痛疗效观察及对凝血项的影响[J].实用中医内科杂志,2009,23(1):4-5.
72.梁丽霞,张秀岩.丹红注射液治疗不稳定性心绞痛48例临床观察[J].河北中医,2009,31(8):1214-1215.
73.王效非.疏血通注射液治疗不稳定性心绞痛50例疗效观察[J].山东医药,2009,49(24):106.
74.骞骏,郭景瑞,段颖.疏血通注射液治疗冠心病68例[J].现代中医药,2009,29(5):6-7.
75.叶任高,陆再英.内科学[M].第6版,北京:人民卫生出版社,2004:263-302.
76.昂德伍德(英),主编.Age-related vascular change.系统病理学.第二版,北京,科学出版社,1999,308-313.
77.王辉,梁金珠,宋敏,李宗铉.中国动脉硬化杂志[J].2002,10(1):45-47.
78.Barrett Connor E.An epidemiologist looks at hormones and heart disease inwomen[J].J Clin Endocrinol Metab,2003,88:4031-4042.
79.Kalin MF,Zumoff B1 Sex hormones and coronary disease:a review of theclinical studies[J].Steroids,1990,55:330.
80.Isles CG,Hole DJ,Hawt horne VM,et al1 Relation between coronary risk andcoronary mortality in women of t he Renf rew and Paisley survey:compareison withmen[J].Lancet,1992,339:702-706.
81.动脉系统多部位粥样硬化的进展的危险因素.stroke.2003,34:2374-2719
82.Hajime Takizawa,Takayuki 0htoshi,Ken Ohta,et al.Growth inhibition of humanlung cancer cel l lines in vitro:A possible role in tumor growth via an autoctrnemechanism.Cancer Res,1993,53:4175.
83.王玉香.女性血脂与脂蛋白水平与年龄关系分析[J].中国医药导刊.2008,10(1):122-123,126.
84.赵水平.降血脂防治冠心病的现代观点[J].中华内科杂志.2001,40(5):127.
85.全亚平.冠心病危险因素的临床评价[J].中华预防医学杂志.2003,37(2):98-100.
86.刘力生.高血压[M].北京:人民卫生出版社.2001,257-259.
87.Shen Y,Rattan V,Sultana C,e t al.Cigarette smoke condensate-induced adhes i -on molecule expression and transendothel ial migration of monocytes [J].Am JPhysiol,1996,270(5 Pt 2):H1624.
88.林帕芳,等.吸烟对高血压颈动脉粥样硬化的影响.中国公共卫生,2005,21(8):1003.
89.Saely CH,Drexel H,Sourij H,et al.Key role of postchallenge hypergl-ycemiafor the presence and extent of coronary atherosclerosis:An angiographic study[J].Atherosclerosis,2008Jan8[Epub ahead of print ] .
90.Printseva OYu,Peclo MM,Gown AM.Various cell t ypes in human atheroscleroticlesions express ICAM-1.Further immunocytochemical and immuneochemicalstudies employing monoclonal antibody 10F3.Am J Pathol 1992,140(4):889-896.
91.Schmi d t AM,Crandall J, Hori O,et al.Elevated plasma levels of vascular celladhes ion molecule-1(VCAM-1)in diabetic patients with microalbuminuria:a markerof vascular dysfunction and progressive vascular disease.Br J Haematol.1996,92(3):747-750.
92.Rizzoni D,Muiesan ML,Porteri E,et al.Circulating adhes ion molecules andcarotid artery structural changes in patients with noninsulin dependent diabetesmellitus.J Hum Hypertens.2003,17(7):463-447.
93.唐梦熊.同型半胱氨酸致动脉粥样硬化的发病机制.国外医学.老年医学分册.2001,22(2):51-54.
94.Harker LA,Slichter SJ,Scott CR,et al.Homocysticiremia vasuular injury andalterial thrombosis.NEnglJMed,1974,291(3):537-541.
95.BrattstromL,Wilcken DEL,Ohrvik J，Brudin L.Common methylenetet-rahydrofolatereductase gene mutation leads to hyperhomocysteinemia but not to vasculardisease.The results of a meta-analysis.Circulation 1998,98:2520-6.
96.KrausJP.Biochemistry and molecular geneties of cystathionineβ-synthase deficiency[J ] .Eur J Pediatr,1998,157(2):50-53.
97.Kang SS,Wong PWK,Norusis M.Homocysteinemia due to folate deficiency[ J ]Metabol i sm,1987,36:458-62.
98.Allen RH,Stabler SP,Savage DG. Lindenbaum J . Diagnosis of cobalamin defieiencyJ :usefulness of serum methylmalonic acid and tot a l homocysteine concentrations[J].Am J Hematol,1990,34:90-8.
99.SelhubJ,Jacques PF,WiLson PWF,Rush D,Rosenberg IH.Vitamin status andintake as primary determinants of homocysteinemia in an elderly papulation[J]. J AmMed Assoc,1993,270:2693-8.
100.Klui j tmans LAJ,vander Heuvel LPWJ,Boers GHJ,etal.molecular geneticanalysis inmild hyperhomocysteinemia:a common mutation in the methylenetetahyrdrofolatereductase gene is a genetic risk factor for cardiovascular disease[J].Am JHum Genet,1996,58:35-41.
101.Deloughery TG,Evans A.Sadeghi A.etal.Common mut a t ion in methylenetetrahydrofolatereductase Correlation with homocysteine metabolism and lateonsetvascular disease[J].Circulation,1996,94(12):3074-3078.
102.BostomAG,LathroPL.Hyperhomocysteinemia in end-stage renal disease: prevalence,etiology,and potential relationship to arteriosclerotic outcomes[J].KidneyInt 1997,52:10-20.
103.Amadottir M,Hultberg B,Nilsson-Ehle P,Thysell H.The effect of reducedglomerular rate on plasma total homocysteine concentration[J].Scand J Clin LabInvest,1996,56:41-6.
104.Stabler SP,Marcell PD,Podell ER,Allen RH.Quantitation of total homocyst -eine,total cysteine,and methionine in normal serum and urine using capillary gas chromatography-mass spectrometry.Anal Biochem 1987,162:185-96.
105.Yao ZH,Gross GT.Activation of ATP-sensitive potassium channels lowersthreshold for ischemic precondi t ioning in dogs.AM J Phsiol,1994,267:H1888.
106.Speechly-Dick ME,Grover GJ,Yellon DM.Dose ischemic preconditioning inthe human involve protein kinase C and the ATP dependent K+ channel? Studies ofcontractile function after simulated ischemia in an atrial in vitro model[J].CircRes,1995,77:1030-1035.
107.Wouters MGAJ,Moorrees MTEC,van der Mooren MJ etal.Plasma homocysteineand menopausal status[J].Eur J Clin Invest 1995,25:801-5.
108.Sehul tz JJ,Qian YZ,Gross CJ，et al.The ischemic selective KATP channelantagonist,5-hydroxydecanoat e ,blocks ischemic preconditioning in the rat heart[J].Mol Cell Cardiol,1997,29:1055-1060.
109.高奋,李静梅,肖传实.高同型半胱氨酸血症兔模型动脉粥样硬化的形成[J].中国动脉硬化杂志,2002,10(4):348-349.
110.Poredos P.Endothe l i a l dysfunction in the pathogenesis of atherosclerosis[J]Clin Appl Thromb Hemost,2001,7(4):276-280.
111.Reiner Z,Tedeschi2Reiner E.New information on the pathophysiology o f a t -herosclerosis[J].Lijec Vjesn,2001,123(1-2):26 .
112.Durham PL,Russo AF.Differential regul a t ion of mitogen-activated proteinkinase-responsive genes by the duration of a calcium signal[JI.Mol Endoerinol,2000:14(10):1570-1582.
113.Kaeng W.Lee,Andrew D.Blann,Gregory Y.H.Lip.Inter-relationships of indi -ces of endothelial damage/dysfunction[circulaton endothelial cells,von Wi llebrandfactor and flow-mediated dilatation to t i ssue factor and interleukin-6 in acutecoronary syndromes[J].International Journal of Cardiology,2006,111(2):302-308.
114.Aun Yeong Chong,Gregory Y.H.Lip,Bethan Freestone,Andrew D.Blann.Increased circulation endothelial cells in acute heart failure:Comparasion with vonwillebrand factor and soluble E-selection[J].European Journal of Heart Failure,2006,8(2):167-172.
115.K.Woj tkielewicz,M.Urban,M.Kowalaeski,J.Peczynska,B.Tu-P7:121So-lublethrombomdulin(STM)-A molecular marker of endothelial cell injury in children andadolescents with type 1 diabetes[J].Atherosclerosis Supplements,2006,7(3):211.
116.K.Woj tkielewiez,M.Urban,M.Kowalewski,et al.soluble thrombomodulin(STM)a molecular marker of endothelial cel l injury in children and adolescents withtype diabetes[J].Poster session P7 Basic science(1s tpart),2006,211.
117.Schneiderman J,Sawdey MS,Keeton MR,et al.Increased type1 plasminogenactivator inhibitor gene expression in atherosclerotis human arteries[J].Proc NatlAcad Sci USA,1992,89:6998-7002.
118.Lupu F,Heim DA,Bachmann F,et al.Plas minogen activator expression inhumanatherosclerotic lesions[J].Arterioscler Thromb VaseBiol,1995,15:1444-1455.
119.Schneider DJ,Hayes M,Wadsworth M,et al.Attenuation of neointimal vascularsmooth muscle cellularity in atheroma by plasminogen activator inhibi t o r type 1(PAI-1)[J].J Histochem Cytochem,2004,52(8):1091-1099.
120.Zelewski A,Shi Y,Nardone D,et al.Evidence for reduced fibrinolytic activi -ty in unstable angina at rest clinical,bioche mical and angiographiccorrelates[J].Circulation,1991,83:1685-1691.
121.Haverkate F.Levels of haemostatic factors,atherosclerosis and cardio vasculardisease[J].Vase Pharmacol,2002,39(3):109-112.
122.Ross R.Atherosclerosis-An inflammatory disease[J].N Engl J Med,1999,340(2):115-26.
123.Suzuki A,Hayashida M.lto T et al.Survivin initates cell cycle entry by thecompetitive interaction with Cdk4/p16NK4a and Cdk2/C yclin E complex activation[J].Oncogene.2000,19:3220.
124.杨永宗,主编.动脉粥样硬化性心血管病基础与临床[M].科学出版社,第一版.2004,4:90-95.
125.Speidl WS,Zeiner A,Nikfardjam M,An increase of C-reactive protein i s associated with enhanced activation of endogenous fibrinolysis at baseline but an imparedendothelial fibrinolytic response after venous occlusion[ J ] . J Am Coll Cardiol,2005,45(1):30-4.
126.Liang YJ,Shyu KG,Wang BW,Creactive protein activates the nuclear factorkappaBpathway and induces vascular cel l adhesion molecule-1 expression throughCD32 in human umbilical vein endothelial cells and aortic endothelial cells[J].J MolCell Cardiol,2006,40(3):412-20.
127.Pascrei V,Willerson JT,Yeh ET.Direct proinflammatory effect of creactiveprotein on human endothelial cells[J].Circulation,2000,102(18):2165-8.
128.Pascrei V,Chang JS,`Willerson JT, e t a l.Modul a t ion of creactive proteinmediatedmonocyte chemoattractant protein1 induction in human endothelial cells byanti-atherosclerosis drugs.Circulation,2001,103(21),2531-4.
129.Li J J,Fang C H.C-reactive protein i s not only an inflammatory marker butalso a direct cause of cardiovascular disease[R].Med Hypotheses,2004,62(4):499-506.
130.Osborn L,Hession C,Tizard R,et al.Direct expression cloning of vascularcell adhesion molecule-1,a cytokine-induced endothelial protein that binds tolymphocytes[J].Cell.1989,59(6):1203-1211.
131.Hajiloo i M,Sanati A,Ahmadieh A.Circulating ICAM-1,VCAM-1,E-selecti n ,P-selectin,and TNFRII in patients with coronary artery disease[J].Immunol invest,2004,33(3):263-725.
132.秦彦文,王绿娅,陈保生.比较低密度脂蛋白亚组份对血管细胞黏附分子-1表达的影响[J].中华医学杂志,2004,84(2):159-160.
133.Cybulsky MI,Iiyama K,Li H,et al.A major role for VCAM-1,but not ICAM-1in early atherosclerosis[J].J Clin Invest,2001,107(10):1255-1262.
134. Reilly MP,Wolfe ML,Dykhouse J.Intercellular adhesion molecule1(ICAM-1)gene variant is associated with coronary artery calcification independent ofsoluble ICAM-1 levels[J].J Investig Med,2004,52(8):515-522.
135.Arvanitis DA,Flouris GA,Spandidos DA.Genomic rearrangements onVCAM
1,SELE,APEG1and AIF1 loci in atherosclerosis[J].J Cell Mol Med,2005,9(1):153-159.
136.Arvanitis DA,Flouris GA,Spandidos DA.Genomic rearrangements onVCAM-1,SELE,APEG1and AIF1 loci in a therosclerosis[J].J Cell Mol Med,2005,9(1):153-159.
137.Ellahham S.Role of antip latelet agents in the primary and secondary preventionof atherothrombotic events in high risk-patients[J].South MedJ,2008,101(3):273-283.
138.Chen K,FebbraioM,LiW, e t al.A specific CD36-dependent signaling pathwayis required for platelet activation by oxidized low-density lipop rotein[J].CircRes,2008,102(12):1512-1519.
139.Cines DB,Pollak ES,Buck CA,et al.Endothelial cells in physiology and inthe pathophysiology of vascular disorders[J].B lood,1998,91(10): 3527-3561.
140.Falat i S,Patil S,Gross PL,et al.Platelet PECAM-1 inhibi t s thrombus forma t -ion in vivo[J].B lood,2006,107(2):535-541.
141.Dhanjal TS, Ross EA,Auger JM,et al.Minimal regulation of plat e l e t activei -ty by PECAM-1[J].Platel e t s ,2007,18(1):56-67.
142.王镜岩,朱圣庚,徐长法.生物化学（下册）[M].北京:中国轻工业出版社,2000:284-296.
143.Fischetti F,Carretta R,Borotto G,et al.Fluvastatin t r eatment inhib i t s leucocyteadhesion and extravasation in models of complementmediated acute inflammat i -on[J].Clin Exp Immunol,2004,135:186-193.
144.Sadot ,E,Geiger,B,Oren,M, et a.Down-regulation ofβ-catenin by activatedp53[J].Mol.Cell.Biol.2001,21:6768-6781.
145.Matsuzawa,S.I.and Reed,J.C.Siah-l,siP,and Ebi col laborate in a novel pathwayforβ-catenin degradation linked to p53 responses.Mol.Cel l . 2001,(7):915-926.
146.Anna T,Loukas K,Apostolos P,et al.EP2306,[2-(4-Biphenyl)-4-methyloctahydro-1,4-benzoxazin-2-ol,hydrobromide],a novel squalene synthase inhibitor,reducesatherosclerosis in the cholesterol-fed rabbit[J].J.Pharmacol Exp Ther,2007,323:794-804.
147.Sawada M,Washizuka K,Okumura H.Synthesis and biological activity of anovel squalene epoxidase inhibitor, FR194738[J].Bioorg Med Chem Lett,2004,14(3):633-637.
148.Binet J,Thomas D,Benmbarek A,et al.Structure activity r e l a t ionships ofnewinhibitors of mammalian 2,3-oxide squalene cyclase designed from isoquinoline derivatives[J].Chem Pharm Bull,2002,50(3):316-329.
149.SaadMF,Greco S,Osei K,et al.Ragagl i tazar improves glycemic control andlipid profile in type 2 diabetic subjects:a 12week,doubleblind,placebo-controlleddose-ranging study with an open pioglitazone arm [J].Diabetes Care,2004,27:1324-1329.
150.OliverWR,Shenk JL,Snaith MR,et al.A selective peroxisome proliferatorsactivated receptor delta agonist promotes reverse cholesterol transport[J].Proc NatlAcad SciUSA,2001,98:5306-5311.
151.李史清.清热泻火为主治疗颈动脉粥样硬化疗效观察[J].山东中医药大学学报,2010,34(2):136-139.
152.Langford EJ,Wainwright RJ,Martin JF.Platelet act ivation in acute myocardialinfarction and unstable angina is inhibited by n i t r i c oxide donors[J].ArteriosclerThromb VascBiol,1996,16:51-55.
153.Ferns GA,Forster L,Stewart Lee A,et al.Probucol inhibits neointimal thickeningand macrophage accumulation after balloon injury in the cholesterolfed rabbit[J].Proc Natl Acad Sci USA,1992,89:11312-11316.
154.曹剑,朱冰坡,范利,等.普罗布考对老年下肢动脉硬化症的抗氧化和抗炎症作用[J].中国动脉硬化杂志,2006,14(4):336-338.
155.郝冰,孟晓萍,等.普罗布考对冠心病患者血清中MMP-2的抑制作用[J].吉林大学学报(医学版),2007,33(3):559-561.
156.足鼎良.钙拮抗剂的抗动脉粥样硬化作用[J].中国医药刊,2000,2,(4):6-7.
157.陈宁南,刘中勇.不稳定性心绞痛发病机制与防治措施探讨[J].实用中西医结合临床,2005,5(6):85-86,92.
158.林蓉,甘伟杰.药物治疗动脉粥样硬化新途径抗炎作用[J].中国药理学通报2004,20(5):499-503.
159.田然,张抒扬.冠状动脉粥样硬化性心脏病的基因治疗[J].中国医药,2006,1(11):702-704.
160.Libby P.Inflammation in atherosclerosis [J].Nature,2002,420(6917):868-874.
161.Fredrikson GN,Andersson L,Soderberg I,et al,Atherop rotective immunizationwith MDA-modified apoB-100 peptide sequences is associated with activationof Th2 specific antibody expression[J].Autoimmunity,2005,38 (2):171-179.
162.Komori T.CETi21,AVANT[J].Curr Opin Investig Drugs,2004,5(3):334-338.
163.Klenk E.Uber die ganglioside,eine neue gruppe von zuckerhal tige gehirnli -poiden Hoppe-Seyler’s[J].Physiol.Chem,1942,273:76-86.
164.Hess,HH,Stotb’n P,and Sprinkle K.Gangliosides in frogretinal rod outersegment membranes[J].J.Neurochem,1976,26:621-623.
165.王晓东,吴英良,山形贞子.GD1a对基质金属蛋白酶-9在不同细胞类型中表达的调控作用[J].沈阳药科大学学报,2009,26(6):493-501.
166.张梅,黄体钢,周丽娟,等.急性冠状动脉综合征患者MMP-9、MMP-2的临床意义[J].中国心血管杂志,2006,11(5):336.
167.Lang Z,Guerrera M,Li R,Ladisch S.Ganglioside GD1a enhancesVEGF-inducedendothelial cell proliferation and migration[J].Biochem Biophys Res Commol /Lun,2001,282(4):1031-7.
168.BrienER,GarvinMR,DevR,etal.Angiogenesisinhumancoro-naryatheros cleroticplaques[J].AmJPathol,1994,145:883-894.
169.Connolly DT,Olander JV,Heuvelman D,et al.Human vascular permeabilityfactor.Isolation from U937 cells[J].J Biol Chem,1989,264:20017-20024.
170.Tuder RM,BE Flock,and NF Voelkel.Increased gene expression for VEGFand VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronichypoxia[J].J Clin Invest,1995,1798-807.
171. Brown LF,Detmor M,Claffey K,et al.Regulation of angiogenesis(Goldberg,ID,and Rosen EM,eds). Birkhauser,Boston,MA,1997:233-269.
172.Netifeld G,Gohen T,Gengrinovitch S,et al.Vascular endothelial growth factor(VEGF)and its receptors[J].FASEB J,1999,13:9- 22.
173.吴健宇,穆静,李仪奎.血清药理实验中异种动物血清对细胞的毒性作用和灭活后的减毒作用[J].中国药理学通报,2000,16(1):118.
174.王力倩,李仪奎,符胜光,等.血清药理学方法研究探索[J].中药药理与临床,1997,13(2):35.
175.刘平.专题笔谈[J].中国中西医结合杂志,1999,19(5):263.
176.崔晓兰,贺玉琢,高英杰,等.中药复方血清药理研究方法学探讨[J].中国实验方剂学杂志,1998,4(3):45.
177.李仪奎,吴健宇.血清药理实验中采血时间的通法方案[J].中国药理学通报,1999,15(6):569.
178.周明眉,杨奎,姜远平,等.中药血清药理学的方法学研究（Ⅳ）--采血时间的确定及时效关系研究[J].中药药理与临床,1998,14(增):110.
179.李仪奎,等.中药药理实验方法学(第二版)[M].上海科学技术出版社,2006:50-53.
180.Ross R.The pathogenesis of atherosclerosis-an update[J]. N Engl J Med,1986,314 (8): 488-500.
181.袁红洁.氧自由基对血管内皮细胞周期及其凋亡水平的影响[J].南京医科大学学报,1999,19:396-397.
182.Diana A.Antioxidant defences against reactive oxygen species causinggenetic and other damage[J].Mutation Research,1996,350:103-108.
183.Halliwell B.,Aruoma O.L.DNA damage by oxygen derived species.its mechanismand measurement i n mammalian system[J].FEBS Lett,1991,281:9-19.
184.袁秉祥,等.酸枣仁总皂甙对大鼠血脂和血脂蛋白胆固醇的影响[J].中国药理学通报,1990,6(l):34.
185.陈一,钟正贤,黄凤娇,等.中药肉桂的药理研究(第一报):对血液和心血管系统的影响[J].中药通报,1981,(5):32.
186.Molnar P,KawaseM,Satoh K,et al.Biological activity of carotenoids in redpaprika,Vnlencia orange and Golden delicious apple[J].Phytother Res, 2005,19(8):700-707.
187.吉中强,宋鲁卿,牛其昌.15种理气中药体外对人血小板聚集的影响[J].中草药,2001,32(5):428-430.
188.PengW,JinL,Hendersonq,et al.Mapping herpes simplex virus type l latencyAssociated transcript sequences that protect from apoptosis mediated by a plasmidExperssing caspase-8[J].J Neurovirol,2004,10(4):260-5.
189.Chuderland D and Seger R.Protein-protein interactions in the regulation ofthe extracellular singal-regulated kinase[J].Mol Biotechnol,2005,29(1):57-74.
190.Hindley A and Kolch W.Exrtacellular singal regulated kinase(ERK)/mitogen activated protein kinase(MAPK)-independent functions of Raf kinases[J].JCell Sci,2002,115(8):1575-81.
191.李凤焕,沈德诚,陈桂彬,等. CD9抗原在白血病细胞上的表达及意义[J].中华血液学杂志,1998,19(3):155-156.
192.彭林,李家增.CD9抗原与血小板活化[J].血栓与止血学杂志,1995,2(4):175-177.
193.Bazzoni G,Martinez Estrada OM,Muel l e r F,et al.Homophilic interacttion ofjunctiona l adhesion molecule[J].Biol Chem,2000,275:30970-30976.
194.Thomas FC,Sheth B,Eckert JJ,et al.Contribution of JAM-1 to epithelial differentiationand tight-junction biogenesis in the mouse preimplantation embryo[ J ] .Cell Science,2004,117:5599-5608.
195.Ermert L,Bruckner H,Walmarath D.Rol e of endothelial cytoskeleton in highpermeability edema due to botulinum C2 toxin in perfused rabbit lungs[J].Am JPhysiol,1995,268:L753-761.
196.Thurston G,Baldwin AL.Changes in endothelial act in cytoskeleton i n venul -es with time after histamine treatment[J].Am J Physiol,1995,269:H1528-1537.
197.MoriyaY,Nakamura T,Okamura N,et al.Comparison of synthetic DNA templateswith authent i c cDNA t emplates in terms of quantification by real-time quanti t -ative reverse transcription polymerase chain reaction[J].Biol Pharm Bull,2006,29:535-8.
198.Brettar I,Labrenz M,Flavier S,et al.Ident i f i c a t ion of a Thiomicrospira deni -trificans-like epsilonproteobacterium asa catalyst for autotrophic denitrification inthe central Baltic Sea[J].Appl Environ Microbiol,2006,72:1364-72.
199.Dussaul t AA, Pouliot M. Rapid and s imple comparison of messenger RNAlevels using real-timePCR[J].Biol Proced Online,2006,8:l-10.
200.Ferrara N.Vascular endothelial growth factor:basic science and clinicalprogress[J].Endocr Rev, 2004,25:581-611.
2.梁煜,林代华,王清.气虚血瘀是冠心病的病机关键释义[J].中医药学刊,2003,21(4):588-589.
3.解民.从肝论治冠心病心绞痛的临床观察[J].吉林中医药,2002,22(4):5.
4.黎运富,彭素娟.中西医结合治疗冠心病不稳定性心绞痛56例总结[J].中医药药导报,2007,13(1):27-28.
5.祖丽华,秦玖刚.宣肺解郁汤联合西药治疗冠心病心绞痛40例[J].湖南中医药导报,2001,7(12):589,594.
6.樊瑞红.马连珍温阳活血法治疗冠心病心绞痛经验[J]辽宁中医杂志,2002,29(2):72.
7.陈维琴.黄蔑合丹参注射液治疗冠心病心绞痛40例[J].四川中医,2001,19(3):37-38.
8.于涛,曹洪欣.胸痹(冠心病)病机演变探微[J].中医药信息,2004,21(2):1-3.
9.杨传彪,周民权.论补养心阴法是治疗冠心病的重要方法[J].中国中医基础医学杂志,1998,4(6):45-47.
10.韩若冰.阴虚心痹临床探理[J].辽宁中医杂志,1987,(3):10-12.
11.程小曲.痰浊型冠心病与血脂、脂蛋白、载脂蛋白的关系及痰浊形成机理的探讨[J].新中医.1994,26(3):7-9.
12.王东生,袁肇凯,余亚明.痰瘀与动脉粥样硬化相关性探讨[J].山东中医药大学学报,2003,27(3):162-164.
13.范现超,张国平,唐明,等.从毒论治动脉粥样硬化初探[J].山东中医杂志,2004,23(5):261-263.
14.陆新.益气化湿活血通脉法治疗不稳定型心绞痛的临床观察[J].四川中医,2007,25(6):49-51.
15.董扬洲,毛湘屛.益气活血复脉汤治疗稳定型冠心病心绞痛32例临床观察[J].中医药导报,2008,14(7):20-21.
16.孙国柱.益气活血法治疗气虚血瘀型不稳定性心绞痛临床研究[J].河南中医学院学报,2005,20(4):35-36.
17.曹洪欣,殷惠军,张腾.温心胶囊抗动脉粥样硬化的形态学研究[J].中国中医药科技,2001,8(1):39.
18.唐丹丽,曹洪欣,张华敏.温阳益心法对动脉粥样硬化大鼠血清C反应蛋白和白细胞介素-6水平的影响[J].中国中医药信息杂志,2007,14(7):29-30.
19.孟强.通补结合治疗冠心病心绞痛66例疗效观察[J].山西中医,2005,21(6):18.
20.李晓,丁书文,姜萍.心和颗粒剂保护冠心病患者血管内皮损伤的临床研究[J].中医杂志,2000,41(11):661-663.
21.韩学杰.痰瘀同治方治疗冠心病心绞痛的临床研究[J].中国中医急症,1999,8(5):212-215.
22.李东柏.联用血府逐瘀胶囊治疗冠心病稳定性心绞痛40例的临床观察[J].北京中医药,2008,27(10):810-811.
23.何红涛.汪慰寒治疗冠心病心绞痛经验[J].辽宁中医药杂志,2006,33(1):15.
24.王嵩,刘煜德,李荣,等.清热解毒法对50例动脉粥样硬化患者血脂、纤维蛋白原、D-二聚体的干预作用[J].山西中医,2009,24(6):46-48.
25.王振涛,韩丽华,朱明军,等.孙建芝教授辨治冠心病经验[J].第十次全国中医心病学术年会论文集,2008:285-288.
26.吴耀南,谢俊杰,许正锦.路志正调理脾胃治疗胸痹的学术思想浅析[J].北京中医.2006,25(2):88-89.
27.刘侠,高彩霞,周玉凤.调理脾胃法治疗胸痹心痛100例[J].新中医,2002,34(7):55-56.
28.牛永军,曹雪梅.从脾胃论治胸痹举隅[J].实用中医内科杂志,2007,21(1):43.
29.罗陆一.从肾论治冠心病机理例析[J].中医药学刊,2005,23(4):588-589.
30.王剑,黄水清,徐志伟.瓜蒌薤白半夏汤对兔动脉粥样硬化模型主动脉蛋白聚糖的作用[J].中国动脉硬化杂志,2008,16(4):290-292.
31.何银辉,蔡奕,罗仕德.加味瓜蒌薤白半夏汤治疗冠心病心绞痛58例临床观察[J].中医药导报,2006,12(2):21-23.
32.潘健.中药治疗不稳定型心绞痛100例分析[J].实用中医内科杂志,2005,9(3):264.
33.王凤儒,李凤霞,戚彬.血府逐瘀汤治疗不稳定型心绞痛心血瘀阻型30例临床观察[J],黑龙江医药,2008,21(6):85-86.
34.文志斌,李俊成,何晓凡,等.四物汤对实验性血栓形成的影响[J].中国危重急救医学,1997,9(3):139-141.
35.邓春雷,陈熙.四物汤对血管内皮细胞分泌组织因子及其抑制物的影响[J].南华大学学报,2001,29(2);126-129.
36.蔡冬梅,殷胜利.吴伟康等.探讨补阳还五汤治疗气虚血瘀型冠心病的临床疗效以及与一氧化氮(NO)的关系[J].现代医学杂志,2004,32(1):5.
37.尚改萍,文志斌,何晓凡,等.补阳还五汤抗家兔动脉粥样硬化形成及机制[J].中国动脉硬化杂志,2002,10(2):112-114.
38.刘发益,文志斌,尚改萍,等.补阳还五汤抗家兔动脉粥样硬化形成的实验研究[J].湖南医科大学学报,2000,25(l):33-35.
39.徐丽萍.四逆汤的药理研究进展[J].中国药事,2002,6(l6):373.
40.高岚.四逆汤对左心室舒张功能的影响[J].现代中西医结合杂志,2000,9(2):112
41.孙慧兰,吴伟康.四逆汤有效成分不同组合抗心肌缺血再灌注损伤的作用研究[J].中草药,2002,33(4):333.
42.马文英,杨家声,弓翠春.复方丹参滴丸对血脂和血流动力学的影响[J].解放军药学学报,2001,17(1):47-81.
43.王有万,复方丹参滴丸对冠心病冠状动脉侧支循环和血运重建的临床观察[J].陕西中医学院学报,2008,31(1):25-26.
44.李耀民,刘向群,陈焕芹,等.复方丹参滴丸对大鼠动脉粥样硬化及TAFI水平的影响[J].中国老年学杂志,2009,29:280-281.
45.李艳平,席云霞.复方丹参滴丸治疗稳定型心绞痛疗效观察[J].临床军医杂志,2006,34(6):673-674.
46.黄元伟,王洪巨.通心络对不稳定型心绞痛患者血管内皮功能影响的临床研究[J].中国医学论坛报,2004,20.
47.李晋芳,胡长林,谢运兰,等.通心络对颈动脉粥样硬化炎性机制作用的临床研究[J].重庆医学,2006,35(8):712-713.
48.李越凡.心可舒治疗不稳定心绞痛疗效观察[J].中国社区医师,2006,8(15):64.
49.姜开余,顾振纶,阮长耿,等.丹参素对CDllb、P-selectin、ICAM-l、VCAM-l、E-selectin表达的影响.中国药理学通报,2001,16(6):682-5.
50.ChenYH,LinSJ,KuHH.Salvianolic acid B attenuates VCAM-1 and ICAM1expression in TNF-alpha-treated human aortic endothelial cell s [ J ] .J Cell Biochem,2001,82(3):512-21.
51.徐东波,张军平,张文志,等.丹参注射液对血管内皮细胞氧化损伤保护作用的实验研究[J].天津医科大学学报,2001,7(1):21-24.
52.侯团章.中草药提取物[M].中国医药科技出版社,2004,128-136.
53.吴勇,欧阳静萍,涂淑珍,等.黄芪多糖对动脉粥样硬化内皮细胞损伤的影响[J].湖北中医学院学报,2002,4(1):21-22.
54.杨五彪,陈群力,马灵筠,等.黄芪多糖对兔动脉粥样硬化血管内皮细胞功能的影响[J].陕西医学杂志,2005,8(34):914-918.
55.黄进宇,单江,徐耕,等.黄芪抑制血管平滑肌细胞增殖及其作用机制[J].中国现代应用药学杂志,2003,20:277-278.
56.WangM,Yang K E,Zhao D,et al.Effect of Panaxadiol Saponins on LPO, SODin Swimming Training Rats[J].Med Sci,2001,27(4):358-360.
57.李凤娥,孔繁利,李威.人参二醇组皂苷抗动脉粥样硬化作用实验研究[J].北华大学学报(自然科学版),2009,10(6):498-500.
58.戴汉云,等.绞股蓝皂贰对各种脂蛋白的影响[J].中草药,1989,20(4):172.
59.耿文奎,等.绞股蓝提取液对大鼠T淋巴细胞及脂类代谢的影响[J].广西医学,1988,10(l ) : 8 .
60.陈献明,等.绞股蓝总皂贰对鹤鹑实验性动脉粥样硬化预防作用的研究[J].山东医药工业,1992,11(l):22.
61.黄红林,尹卫东,廖端芳,等.绞股蓝总皂普对兔实验性动脉粥样硬化斑块形成的影响[J].中国动脉硬化杂志,1998,6(4):287.
62.Rhule A,N avarro S,Smith J R,et al.Panax notoginseng a t tenuates LPS-inducedproinflammatory mediators in RAW 264.7 cells [J].J E thnopharmacol, 2006,106(1):121-128.
63.闫彦芳,张壮,孙塑伦,等.三七总皂苷及其主要成分对血管内皮细胞缺氧损伤的保护作用[J].中国实验方剂学杂志,2002,8(1):34-37.
64.曾桂凤,刘建勋,李澎,等.丹参三七不同配比对缺氧复氧损伤人脐静脉内皮细胞的保护作用[J].精细化工,2006,23(2):126-129.
65.张希成,李刚.水蛭的药理与临床应用[J].医药产业资讯,2006,3(17):123.
66.刘晓颖,李凤文,张立石.水蛭对实验性动脉粥样硬化家兔血管内皮功能障碍的影响[J].中国中医基础医学杂志,1998,4(3):15-17.
67.才晓君,毕秀萍,王磊.生脉注射液对老年不稳定性心绞痛患者血浆炎性因子的影响[J].中国老年学杂志,2007,27:2228-2229.
68.汪根水.瓜蒌葛参汤联合生脉注射液治疗冠心病58例临床观察[J].中国中医药科技,2006,13(2):102.
69.贺厚毅,陈卫强.黄芪注射液治疗不稳定型心绞痛疗效观察[ J ] .中国自然医学杂志,2003,5(2):90-91.
70.郭跃来,于耀杰.黄芪注射液治疗老年不稳定型心绞痛30例[J].陕西中医,2006,27(7):846-847.
71.陈波,闫智杰,辛乐加.丹红注射液治疗不稳定型心绞痛疗效观察及对凝血项的影响[J].实用中医内科杂志,2009,23(1):4-5.
72.梁丽霞,张秀岩.丹红注射液治疗不稳定性心绞痛48例临床观察[J].河北中医,2009,31(8):1214-1215.
73.王效非.疏血通注射液治疗不稳定性心绞痛50例疗效观察[J].山东医药,2009,49(24):106.
74.骞骏,郭景瑞,段颖.疏血通注射液治疗冠心病68例[J].现代中医药,2009,29(5):6-7.
75.叶任高,陆再英.内科学[M].第6版,北京:人民卫生出版社,2004:263-302.
76.昂德伍德(英),主编.Age-related vascular change.系统病理学.第二版,北京,科学出版社,1999,308-313.
77.王辉,梁金珠,宋敏,李宗铉.中国动脉硬化杂志[J].2002,10(1):45-47.
78.Barrett Connor E.An epidemiologist looks at hormones and heart disease inwomen[J].J Clin Endocrinol Metab,2003,88:4031-4042.
79.Kalin MF,Zumoff B1 Sex hormones and coronary disease:a review of theclinical studies[J].Steroids,1990,55:330.
80.Isles CG,Hole DJ,Hawt horne VM,et al1 Relation between coronary risk andcoronary mortality in women of t he Renf rew and Paisley survey:compareison withmen[J].Lancet,1992,339:702-706.
81.动脉系统多部位粥样硬化的进展的危险因素.stroke.2003,34:2374-2719
82.Hajime Takizawa,Takayuki 0htoshi,Ken Ohta,et al.Growth inhibition of humanlung cancer cel l lines in vitro:A possible role in tumor growth via an autoctrnemechanism.Cancer Res,1993,53:4175.
83.王玉香.女性血脂与脂蛋白水平与年龄关系分析[J].中国医药导刊.2008,10(1):122-123,126.
84.赵水平.降血脂防治冠心病的现代观点[J].中华内科杂志.2001,40(5):127.
85.全亚平.冠心病危险因素的临床评价[J].中华预防医学杂志.2003,37(2):98-100.
86.刘力生.高血压[M].北京:人民卫生出版社.2001,257-259.
87.Shen Y,Rattan V,Sultana C,e t al.Cigarette smoke condensate-induced adhes i -on molecule expression and transendothel ial migration of monocytes [J].Am JPhysiol,1996,270(5 Pt 2):H1624.
88.林帕芳,等.吸烟对高血压颈动脉粥样硬化的影响.中国公共卫生,2005,21(8):1003.
89.Saely CH,Drexel H,Sourij H,et al.Key role of postchallenge hypergl-ycemiafor the presence and extent of coronary atherosclerosis:An angiographic study[J].Atherosclerosis,2008Jan8[Epub ahead of print ] .
90.Printseva OYu,Peclo MM,Gown AM.Various cell t ypes in human atheroscleroticlesions express ICAM-1.Further immunocytochemical and immuneochemicalstudies employing monoclonal antibody 10F3.Am J Pathol 1992,140(4):889-896.
91.Schmi d t AM,Crandall J, Hori O,et al.Elevated plasma levels of vascular celladhes ion molecule-1(VCAM-1)in diabetic patients with microalbuminuria:a markerof vascular dysfunction and progressive vascular disease.Br J Haematol.1996,92(3):747-750.
92.Rizzoni D,Muiesan ML,Porteri E,et al.Circulating adhes ion molecules andcarotid artery structural changes in patients with noninsulin dependent diabetesmellitus.J Hum Hypertens.2003,17(7):463-447.
93.唐梦熊.同型半胱氨酸致动脉粥样硬化的发病机制.国外医学.老年医学分册.2001,22(2):51-54.
94.Harker LA,Slichter SJ,Scott CR,et al.Homocysticiremia vasuular injury andalterial thrombosis.NEnglJMed,1974,291(3):537-541.
95.BrattstromL,Wilcken DEL,Ohrvik J，Brudin L.Common methylenetet-rahydrofolatereductase gene mutation leads to hyperhomocysteinemia but not to vasculardisease.The results of a meta-analysis.Circulation 1998,98:2520-6.
96.KrausJP.Biochemistry and molecular geneties of cystathionineβ-synthase deficiency[J ] .Eur J Pediatr,1998,157(2):50-53.
97.Kang SS,Wong PWK,Norusis M.Homocysteinemia due to folate deficiency[ J ]Metabol i sm,1987,36:458-62.
98.Allen RH,Stabler SP,Savage DG. Lindenbaum J . Diagnosis of cobalamin defieiencyJ :usefulness of serum methylmalonic acid and tot a l homocysteine concentrations[J].Am J Hematol,1990,34:90-8.
99.SelhubJ,Jacques PF,WiLson PWF,Rush D,Rosenberg IH.Vitamin status andintake as primary determinants of homocysteinemia in an elderly papulation[J]. J AmMed Assoc,1993,270:2693-8.
100.Klui j tmans LAJ,vander Heuvel LPWJ,Boers GHJ,etal.molecular geneticanalysis inmild hyperhomocysteinemia:a common mutation in the methylenetetahyrdrofolatereductase gene is a genetic risk factor for cardiovascular disease[J].Am JHum Genet,1996,58:35-41.
101.Deloughery TG,Evans A.Sadeghi A.etal.Common mut a t ion in methylenetetrahydrofolatereductase Correlation with homocysteine metabolism and lateonsetvascular disease[J].Circulation,1996,94(12):3074-3078.
102.BostomAG,LathroPL.Hyperhomocysteinemia in end-stage renal disease: prevalence,etiology,and potential relationship to arteriosclerotic outcomes[J].KidneyInt 1997,52:10-20.
103.Amadottir M,Hultberg B,Nilsson-Ehle P,Thysell H.The effect of reducedglomerular rate on plasma total homocysteine concentration[J].Scand J Clin LabInvest,1996,56:41-6.
104.Stabler SP,Marcell PD,Podell ER,Allen RH.Quantitation of total homocyst -eine,total cysteine,and methionine in normal serum and urine using capillary gas chromatography-mass spectrometry.Anal Biochem 1987,162:185-96.
105.Yao ZH,Gross GT.Activation of ATP-sensitive potassium channels lowersthreshold for ischemic precondi t ioning in dogs.AM J Phsiol,1994,267:H1888.
106.Speechly-Dick ME,Grover GJ,Yellon DM.Dose ischemic preconditioning inthe human involve protein kinase C and the ATP dependent K+ channel? Studies ofcontractile function after simulated ischemia in an atrial in vitro model[J].CircRes,1995,77:1030-1035.
107.Wouters MGAJ,Moorrees MTEC,van der Mooren MJ etal.Plasma homocysteineand menopausal status[J].Eur J Clin Invest 1995,25:801-5.
108.Sehul tz JJ,Qian YZ,Gross CJ，et al.The ischemic selective KATP channelantagonist,5-hydroxydecanoat e ,blocks ischemic preconditioning in the rat heart[J].Mol Cell Cardiol,1997,29:1055-1060.
109.高奋,李静梅,肖传实.高同型半胱氨酸血症兔模型动脉粥样硬化的形成[J].中国动脉硬化杂志,2002,10(4):348-349.
110.Poredos P.Endothe l i a l dysfunction in the pathogenesis of atherosclerosis[J]Clin Appl Thromb Hemost,2001,7(4):276-280.
111.Reiner Z,Tedeschi2Reiner E.New information on the pathophysiology o f a t -herosclerosis[J].Lijec Vjesn,2001,123(1-2):26 .
112.Durham PL,Russo AF.Differential regul a t ion of mitogen-activated proteinkinase-responsive genes by the duration of a calcium signal[JI.Mol Endoerinol,2000:14(10):1570-1582.
113.Kaeng W.Lee,Andrew D.Blann,Gregory Y.H.Lip.Inter-relationships of indi -ces of endothelial damage/dysfunction[circulaton endothelial cells,von Wi llebrandfactor and flow-mediated dilatation to t i ssue factor and interleukin-6 in acutecoronary syndromes[J].International Journal of Cardiology,2006,111(2):302-308.
114.Aun Yeong Chong,Gregory Y.H.Lip,Bethan Freestone,Andrew D.Blann.Increased circulation endothelial cells in acute heart failure:Comparasion with vonwillebrand factor and soluble E-selection[J].European Journal of Heart Failure,2006,8(2):167-172.
115.K.Woj tkielewicz,M.Urban,M.Kowalaeski,J.Peczynska,B.Tu-P7:121So-lublethrombomdulin(STM)-A molecular marker of endothelial cell injury in children andadolescents with type 1 diabetes[J].Atherosclerosis Supplements,2006,7(3):211.
116.K.Woj tkielewiez,M.Urban,M.Kowalewski,et al.soluble thrombomodulin(STM)a molecular marker of endothelial cel l injury in children and adolescents withtype diabetes[J].Poster session P7 Basic science(1s tpart),2006,211.
117.Schneiderman J,Sawdey MS,Keeton MR,et al.Increased type1 plasminogenactivator inhibitor gene expression in atherosclerotis human arteries[J].Proc NatlAcad Sci USA,1992,89:6998-7002.
118.Lupu F,Heim DA,Bachmann F,et al.Plas minogen activator expression inhumanatherosclerotic lesions[J].Arterioscler Thromb VaseBiol,1995,15:1444-1455.
119.Schneider DJ,Hayes M,Wadsworth M,et al.Attenuation of neointimal vascularsmooth muscle cellularity in atheroma by plasminogen activator inhibi t o r type 1(PAI-1)[J].J Histochem Cytochem,2004,52(8):1091-1099.
120.Zelewski A,Shi Y,Nardone D,et al.Evidence for reduced fibrinolytic activi -ty in unstable angina at rest clinical,bioche mical and angiographiccorrelates[J].Circulation,1991,83:1685-1691.
121.Haverkate F.Levels of haemostatic factors,atherosclerosis and cardio vasculardisease[J].Vase Pharmacol,2002,39(3):109-112.
122.Ross R.Atherosclerosis-An inflammatory disease[J].N Engl J Med,1999,340(2):115-26.
123.Suzuki A,Hayashida M.lto T et al.Survivin initates cell cycle entry by thecompetitive interaction with Cdk4/p16NK4a and Cdk2/C yclin E complex activation[J].Oncogene.2000,19:3220.
124.杨永宗,主编.动脉粥样硬化性心血管病基础与临床[M].科学出版社,第一版.2004,4:90-95.
125.Speidl WS,Zeiner A,Nikfardjam M,An increase of C-reactive protein i s associated with enhanced activation of endogenous fibrinolysis at baseline but an imparedendothelial fibrinolytic response after venous occlusion[ J ] . J Am Coll Cardiol,2005,45(1):30-4.
126.Liang YJ,Shyu KG,Wang BW,Creactive protein activates the nuclear factorkappaBpathway and induces vascular cel l adhesion molecule-1 expression throughCD32 in human umbilical vein endothelial cells and aortic endothelial cells[J].J MolCell Cardiol,2006,40(3):412-20.
127.Pascrei V,Willerson JT,Yeh ET.Direct proinflammatory effect of creactiveprotein on human endothelial cells[J].Circulation,2000,102(18):2165-8.
128.Pascrei V,Chang JS,`Willerson JT, e t a l.Modul a t ion of creactive proteinmediatedmonocyte chemoattractant protein1 induction in human endothelial cells byanti-atherosclerosis drugs.Circulation,2001,103(21),2531-4.
129.Li J J,Fang C H.C-reactive protein i s not only an inflammatory marker butalso a direct cause of cardiovascular disease[R].Med Hypotheses,2004,62(4):499-506.
130.Osborn L,Hession C,Tizard R,et al.Direct expression cloning of vascularcell adhesion molecule-1,a cytokine-induced endothelial protein that binds tolymphocytes[J].Cell.1989,59(6):1203-1211.
131.Hajiloo i M,Sanati A,Ahmadieh A.Circulating ICAM-1,VCAM-1,E-selecti n ,P-selectin,and TNFRII in patients with coronary artery disease[J].Immunol invest,2004,33(3):263-725.
132.秦彦文,王绿娅,陈保生.比较低密度脂蛋白亚组份对血管细胞黏附分子-1表达的影响[J].中华医学杂志,2004,84(2):159-160.
133.Cybulsky MI,Iiyama K,Li H,et al.A major role for VCAM-1,but not ICAM-1in early atherosclerosis[J].J Clin Invest,2001,107(10):1255-1262.
134. Reilly MP,Wolfe ML,Dykhouse J.Intercellular adhesion molecule1(ICAM-1)gene variant is associated with coronary artery calcification independent ofsoluble ICAM-1 levels[J].J Investig Med,2004,52(8):515-522.
135.Arvanitis DA,Flouris GA,Spandidos DA.Genomic rearrangements onVCAM
1,SELE,APEG1and AIF1 loci in atherosclerosis[J].J Cell Mol Med,2005,9(1):153-159.
136.Arvanitis DA,Flouris GA,Spandidos DA.Genomic rearrangements onVCAM-1,SELE,APEG1and AIF1 loci in a therosclerosis[J].J Cell Mol Med,2005,9(1):153-159.
137.Ellahham S.Role of antip latelet agents in the primary and secondary preventionof atherothrombotic events in high risk-patients[J].South MedJ,2008,101(3):273-283.
138.Chen K,FebbraioM,LiW, e t al.A specific CD36-dependent signaling pathwayis required for platelet activation by oxidized low-density lipop rotein[J].CircRes,2008,102(12):1512-1519.
139.Cines DB,Pollak ES,Buck CA,et al.Endothelial cells in physiology and inthe pathophysiology of vascular disorders[J].B lood,1998,91(10): 3527-3561.
140.Falat i S,Patil S,Gross PL,et al.Platelet PECAM-1 inhibi t s thrombus forma t -ion in vivo[J].B lood,2006,107(2):535-541.
141.Dhanjal TS, Ross EA,Auger JM,et al.Minimal regulation of plat e l e t activei -ty by PECAM-1[J].Platel e t s ,2007,18(1):56-67.
142.王镜岩,朱圣庚,徐长法.生物化学（下册）[M].北京:中国轻工业出版社,2000:284-296.
143.Fischetti F,Carretta R,Borotto G,et al.Fluvastatin t r eatment inhib i t s leucocyteadhesion and extravasation in models of complementmediated acute inflammat i -on[J].Clin Exp Immunol,2004,135:186-193.
144.Sadot ,E,Geiger,B,Oren,M, et a.Down-regulation ofβ-catenin by activatedp53[J].Mol.Cell.Biol.2001,21:6768-6781.
145.Matsuzawa,S.I.and Reed,J.C.Siah-l,siP,and Ebi col laborate in a novel pathwayforβ-catenin degradation linked to p53 responses.Mol.Cel l . 2001,(7):915-926.
146.Anna T,Loukas K,Apostolos P,et al.EP2306,[2-(4-Biphenyl)-4-methyloctahydro-1,4-benzoxazin-2-ol,hydrobromide],a novel squalene synthase inhibitor,reducesatherosclerosis in the cholesterol-fed rabbit[J].J.Pharmacol Exp Ther,2007,323:794-804.
147.Sawada M,Washizuka K,Okumura H.Synthesis and biological activity of anovel squalene epoxidase inhibitor, FR194738[J].Bioorg Med Chem Lett,2004,14(3):633-637.
148.Binet J,Thomas D,Benmbarek A,et al.Structure activity r e l a t ionships ofnewinhibitors of mammalian 2,3-oxide squalene cyclase designed from isoquinoline derivatives[J].Chem Pharm Bull,2002,50(3):316-329.
149.SaadMF,Greco S,Osei K,et al.Ragagl i tazar improves glycemic control andlipid profile in type 2 diabetic subjects:a 12week,doubleblind,placebo-controlleddose-ranging study with an open pioglitazone arm [J].Diabetes Care,2004,27:1324-1329.
150.OliverWR,Shenk JL,Snaith MR,et al.A selective peroxisome proliferatorsactivated receptor delta agonist promotes reverse cholesterol transport[J].Proc NatlAcad SciUSA,2001,98:5306-5311.
151.李史清.清热泻火为主治疗颈动脉粥样硬化疗效观察[J].山东中医药大学学报,2010,34(2):136-139.
152.Langford EJ,Wainwright RJ,Martin JF.Platelet act ivation in acute myocardialinfarction and unstable angina is inhibited by n i t r i c oxide donors[J].ArteriosclerThromb VascBiol,1996,16:51-55.
153.Ferns GA,Forster L,Stewart Lee A,et al.Probucol inhibits neointimal thickeningand macrophage accumulation after balloon injury in the cholesterolfed rabbit[J].Proc Natl Acad Sci USA,1992,89:11312-11316.
154.曹剑,朱冰坡,范利,等.普罗布考对老年下肢动脉硬化症的抗氧化和抗炎症作用[J].中国动脉硬化杂志,2006,14(4):336-338.
155.郝冰,孟晓萍,等.普罗布考对冠心病患者血清中MMP-2的抑制作用[J].吉林大学学报(医学版),2007,33(3):559-561.
156.足鼎良.钙拮抗剂的抗动脉粥样硬化作用[J].中国医药刊,2000,2,(4):6-7.
157.陈宁南,刘中勇.不稳定性心绞痛发病机制与防治措施探讨[J].实用中西医结合临床,2005,5(6):85-86,92.
158.林蓉,甘伟杰.药物治疗动脉粥样硬化新途径抗炎作用[J].中国药理学通报2004,20(5):499-503.
159.田然,张抒扬.冠状动脉粥样硬化性心脏病的基因治疗[J].中国医药,2006,1(11):702-704.
160.Libby P.Inflammation in atherosclerosis [J].Nature,2002,420(6917):868-874.
161.Fredrikson GN,Andersson L,Soderberg I,et al,Atherop rotective immunizationwith MDA-modified apoB-100 peptide sequences is associated with activationof Th2 specific antibody expression[J].Autoimmunity,2005,38 (2):171-179.
162.Komori T.CETi21,AVANT[J].Curr Opin Investig Drugs,2004,5(3):334-338.
163.Klenk E.Uber die ganglioside,eine neue gruppe von zuckerhal tige gehirnli -poiden Hoppe-Seyler’s[J].Physiol.Chem,1942,273:76-86.
164.Hess,HH,Stotb’n P,and Sprinkle K.Gangliosides in frogretinal rod outersegment membranes[J].J.Neurochem,1976,26:621-623.
165.王晓东,吴英良,山形贞子.GD1a对基质金属蛋白酶-9在不同细胞类型中表达的调控作用[J].沈阳药科大学学报,2009,26(6):493-501.
166.张梅,黄体钢,周丽娟,等.急性冠状动脉综合征患者MMP-9、MMP-2的临床意义[J].中国心血管杂志,2006,11(5):336.
167.Lang Z,Guerrera M,Li R,Ladisch S.Ganglioside GD1a enhancesVEGF-inducedendothelial cell proliferation and migration[J].Biochem Biophys Res Commol /Lun,2001,282(4):1031-7.
168.BrienER,GarvinMR,DevR,etal.Angiogenesisinhumancoro-naryatheros cleroticplaques[J].AmJPathol,1994,145:883-894.
169.Connolly DT,Olander JV,Heuvelman D,et al.Human vascular permeabilityfactor.Isolation from U937 cells[J].J Biol Chem,1989,264:20017-20024.
170.Tuder RM,BE Flock,and NF Voelkel.Increased gene expression for VEGFand VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronichypoxia[J].J Clin Invest,1995,1798-807.
171. Brown LF,Detmor M,Claffey K,et al.Regulation of angiogenesis(Goldberg,ID,and Rosen EM,eds). Birkhauser,Boston,MA,1997:233-269.
172.Netifeld G,Gohen T,Gengrinovitch S,et al.Vascular endothelial growth factor(VEGF)and its receptors[J].FASEB J,1999,13:9- 22.
173.吴健宇,穆静,李仪奎.血清药理实验中异种动物血清对细胞的毒性作用和灭活后的减毒作用[J].中国药理学通报,2000,16(1):118.
174.王力倩,李仪奎,符胜光,等.血清药理学方法研究探索[J].中药药理与临床,1997,13(2):35.
175.刘平.专题笔谈[J].中国中西医结合杂志,1999,19(5):263.
176.崔晓兰,贺玉琢,高英杰,等.中药复方血清药理研究方法学探讨[J].中国实验方剂学杂志,1998,4(3):45.
177.李仪奎,吴健宇.血清药理实验中采血时间的通法方案[J].中国药理学通报,1999,15(6):569.
178.周明眉,杨奎,姜远平,等.中药血清药理学的方法学研究（Ⅳ）--采血时间的确定及时效关系研究[J].中药药理与临床,1998,14(增):110.
179.李仪奎,等.中药药理实验方法学(第二版)[M].上海科学技术出版社,2006:50-53.
180.Ross R.The pathogenesis of atherosclerosis-an update[J]. N Engl J Med,1986,314 (8): 488-500.
181.袁红洁.氧自由基对血管内皮细胞周期及其凋亡水平的影响[J].南京医科大学学报,1999,19:396-397.
182.Diana A.Antioxidant defences against reactive oxygen species causinggenetic and other damage[J].Mutation Research,1996,350:103-108.
183.Halliwell B.,Aruoma O.L.DNA damage by oxygen derived species.its mechanismand measurement i n mammalian system[J].FEBS Lett,1991,281:9-19.
184.袁秉祥,等.酸枣仁总皂甙对大鼠血脂和血脂蛋白胆固醇的影响[J].中国药理学通报,1990,6(l):34.
185.陈一,钟正贤,黄凤娇,等.中药肉桂的药理研究(第一报):对血液和心血管系统的影响[J].中药通报,1981,(5):32.
186.Molnar P,KawaseM,Satoh K,et al.Biological activity of carotenoids in redpaprika,Vnlencia orange and Golden delicious apple[J].Phytother Res, 2005,19(8):700-707.
187.吉中强,宋鲁卿,牛其昌.15种理气中药体外对人血小板聚集的影响[J].中草药,2001,32(5):428-430.
188.PengW,JinL,Hendersonq,et al.Mapping herpes simplex virus type l latencyAssociated transcript sequences that protect from apoptosis mediated by a plasmidExperssing caspase-8[J].J Neurovirol,2004,10(4):260-5.
189.Chuderland D and Seger R.Protein-protein interactions in the regulation ofthe extracellular singal-regulated kinase[J].Mol Biotechnol,2005,29(1):57-74.
190.Hindley A and Kolch W.Exrtacellular singal regulated kinase(ERK)/mitogen activated protein kinase(MAPK)-independent functions of Raf kinases[J].JCell Sci,2002,115(8):1575-81.
191.李凤焕,沈德诚,陈桂彬,等. CD9抗原在白血病细胞上的表达及意义[J].中华血液学杂志,1998,19(3):155-156.
192.彭林,李家增.CD9抗原与血小板活化[J].血栓与止血学杂志,1995,2(4):175-177.
193.Bazzoni G,Martinez Estrada OM,Muel l e r F,et al.Homophilic interacttion ofjunctiona l adhesion molecule[J].Biol Chem,2000,275:30970-30976.
194.Thomas FC,Sheth B,Eckert JJ,et al.Contribution of JAM-1 to epithelial differentiationand tight-junction biogenesis in the mouse preimplantation embryo[ J ] .Cell Science,2004,117:5599-5608.
195.Ermert L,Bruckner H,Walmarath D.Rol e of endothelial cytoskeleton in highpermeability edema due to botulinum C2 toxin in perfused rabbit lungs[J].Am JPhysiol,1995,268:L753-761.
196.Thurston G,Baldwin AL.Changes in endothelial act in cytoskeleton i n venul -es with time after histamine treatment[J].Am J Physiol,1995,269:H1528-1537.
197.MoriyaY,Nakamura T,Okamura N,et al.Comparison of synthetic DNA templateswith authent i c cDNA t emplates in terms of quantification by real-time quanti t -ative reverse transcription polymerase chain reaction[J].Biol Pharm Bull,2006,29:535-8.
198.Brettar I,Labrenz M,Flavier S,et al.Ident i f i c a t ion of a Thiomicrospira deni -trificans-like epsilonproteobacterium asa catalyst for autotrophic denitrification inthe central Baltic Sea[J].Appl Environ Microbiol,2006,72:1364-72.
199.Dussaul t AA, Pouliot M. Rapid and s imple comparison of messenger RNAlevels using real-timePCR[J].Biol Proced Online,2006,8:l-10.
200.Ferrara N.Vascular endothelial growth factor:basic science and clinicalprogress[J].Endocr Rev, 2004,25:581-611.